ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1558

Serum Cathepsin S and Cystatin C Relation with Carotid Subclinical Atheromatosis in Rheumatoid Arthritis Patients

Beatriz Tejera Segura1, De Vera-González AM2, Raquel López-Mejías3, Miguel A. Gonzalez-Gay4 and Ivan Ferraz-Amaro1, 1Division of Rheumatology, University Hospital of Canary Islands, Tenerife, Spain, 2Central Laboratory Division, University Hospital of Canary Islands, Tenerife, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 4Reumatologia, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, Cholesterol and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular risks. Cathepsin S, a cysteine protease implicated in intracellular and extracellular proteolysis, and its endogenous inhibitor cystatin C has been both associated with increased cardiovascular mortality in general population. 

Objective. To assess if serum cathepsin S and cystatin C, two novel markers of cardiovascular disease risk are associated with subclinical carotid atherosclerosis in RA patients. 

Methods: Serum cystatin C and cathepsin S levels, ultrasound carotid intima-media thickness (cIMT) and carotid plaques were assessed in a cross-sectional study involving 178 RA patients.Multivariate regression analysis was assessed to study the relationship between cathepsin S and cystatin C serum levels and cardiovascular risk factors and disease related data.

Results: Mean cIMT was 0.670 ± 0.143 mm, and 66 patients (37%) had carotid plaques in the carotid ultrasound assessment. Both cystatin C and cathepsin S were significantly associated with hypertension, diabetes and dyslipidemia. Cathepsin S was inversely related with male gender whereas cystatin was strongly associated with age. Regarding RA related data; cathepsin S was associated with disease duration and cystatin C was positively related with higher levels of ESR. Neither positive rheumatoid factor nor prednisone use were associated with cystatin C or cathepsin S. A trend for lower levels of cystatin C was observed in patients undergoing anti-TNF-alpha therapy (log beta coef. -0.20 (-0.44-0.04), p=0.09). An association between disease activity scores with higher levels of cystatin C, but not with cathepsin S, was found. Cystatin C levels were associated with cIMT in the subgroup of patients included in the higher quartile of cIMT (OR 1.31, 95%CI [1.00-1.72], p=0.04) after adjusting for traditional cardiovascular risk factors, age and sex. An association between serum cystatin C levels and carotid plaques was also found in the univariate analysis (OR 1.37, 95%CI [1.06-1.76], p=0.02). However, this significant association was lost after adjusting for traditional cardiovascular risk factors and age. Cathepsin S was not associated with cIMT or carotid plaques.

Conclusion: High cystatin C serum levels identify a subgroup of RA patients with a high risk of subclinical atherosclerotic disease.


Disclosure: B. Tejera Segura, None; D. V. G. AM, None; R. López-Mejías, None; M. A. Gonzalez-Gay, None; I. Ferraz-Amaro, None.

To cite this abstract in AMA style:

Tejera Segura B, AM DVG, López-Mejías R, Gonzalez-Gay MA, Ferraz-Amaro I. Serum Cathepsin S and Cystatin C Relation with Carotid Subclinical Atheromatosis in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/serum-cathepsin-s-and-cystatin-c-relation-with-carotid-subclinical-atheromatosis-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-cathepsin-s-and-cystatin-c-relation-with-carotid-subclinical-atheromatosis-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology